Dr. Reddy's Laboratories (DRREDDY) — Corporate Action

Dr. Reddy's Laboratories reported a 16% YoY revenue increase to ₹53.7 billion in FY25, driven by 23% growth in Global Generics and 145% growth in Europe, with gross margin at 55.6% and net profit up 22% to ₹5.9 billion in Q4FY25. The Board recommended an ₹8 final dividend per share, reappointed G V Prasad for a 5-year term pending shareholder approval, and convened the 41st AGM on July 24, 2025. A 1:5 stock split was approved, converting Rs 5 face value shares into five Rs 1 shares, effective October 28, 2024, with post-split equity shares at 834,455,365. The company also recorded a ₹1,551 million foreign exchange gain reclassification and a ₹473 million deferred tax asset write-off.

📄 View Original Announcement (PDF)

📊 Stock Analysis — DRREDDY ✨ Ask AI About This

About Dr. Reddy's Laboratories Limited (DRREDDY)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,11,568.6 Cr P/E: 20.0 ROE: 16.6% ROCE: 19.7%

View full DRREDDY stock details →

📡 Get AI alerts when DRREDDY files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track DRREDDY — Free

💡 Ask AI about this filing

"How does this corporate action affect Dr. Reddy's Laboratories Limited's outlook?" "What did Dr. Reddy's Laboratories Limited announce on 9 May 2025?" "Is this positive or negative for DRREDDY?"

Ask AI Free →

📊 More DRREDDY filings

See all DRREDDY filings →

🔥 Also filed on 9 May 2025

TITAN Titan Company Limited Financial Results TRENT Trent Limited Financial Results RECLTD REC Limited Financial Results SHRIRAMFIN Shriram Finance Limited Announcement SBIN State Bank of India Financial Results UNIONBANK Union Bank of India Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when DRREDDY files new disclosures

Track DRREDDY filings, board meetings, and corporate actions. Free email alerts at 5 PM.